18-Jun-2026
As U.S. profit margins near record highs, these small-cap stocks lead on profitability
Seeking Alpha News (Thu, 18-Jun 7:43 AM ET)
These small-cap healthcare stocks pair revenue growth with attractive valuations
Seeking Alpha News (Wed, 17-Jun 7:02 AM ET)
Globe Newswire (Mon, 8-Jun 8:30 AM ET)
CorMedix Raises Full-Year Guidance on Robust Q1 Results and Pipeline Momentum
Market Chameleon (Fri, 15-May 7:55 AM ET)
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
Globe Newswire (Fri, 15-May 8:30 AM ET)
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 14-May 7:30 AM ET)
Globe Newswire (Tue, 5-May 8:30 AM ET)
CorMedix to Participate in Needham Virtual Healthcare Conference
Globe Newswire (Tue, 7-Apr 8:30 AM ET)
Market Chameleon (Thu, 5-Mar 2:58 AM ET)
Market Chameleon (Mon, 2-Mar 3:52 AM ET)
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Cormedix trades on the NASDAQ stock market under the symbol CRMD.
As of June 18, 2026, CRMD stock price was flat at $8.67 with 1,918,552 million shares trading.
CRMD has a beta of 0.21, meaning it tends to be less sensitive to market movements. CRMD has a correlation of 0.00 to the broad based SPY ETF.
CRMD has a market cap of $680.09 million. This is considered a Small Cap stock.
Last quarter Cormedix reported $127 million in Revenue and $.43 earnings per share. This beat revenue expectation by $21 million and exceeded earnings estimates by $.10.
In the last 3 years, CRMD traded as high as $17.43 and as low as $2.57.
The top ETF exchange traded funds that CRMD belongs to (by Net Assets): VTI, IWM, VXF, SFLO, IWO.
CRMD has underperformed the market in the last year with a return of -37.8%, while SPY returned +26.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CRMD shares. However, CRMD has outperformed the market in the last 3 month and 2 week periods, returning +34.2% and +5.3%, while SPY returned +11.6% and -1.0%, respectively. This indicates CRMD has been having a stronger performance recently.
CRMD support price is $8.48 and resistance is $8.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRMD shares will trade within this expected range on the day.